Cartesian Therapeutics Reports Q1 2026 Net Loss of $39.2M Amidst Revenue Decline, Secures $14.6M via ATM Offering

summarizeSummary

Cartesian Therapeutics reported a substantial increase in net loss and a sharp decline in revenue for Q1 2026, but bolstered its liquidity with a $14.6 million ATM offering, securing a 12-month cash runway.

check_boxKey Events

• Net Loss Significantly Increases

  The company reported a net loss of $39.2 million for Q1 2026, a 121% increase from the $17.7 million net loss in Q1 2025. This follows a full-year 2025 net loss of $130.3 million.

• Revenue Plummets Year-over-Year

  Total revenue for Q1 2026 was $0.078 million, a 93% decrease compared to $1.1 million in Q1 2025, primarily due to reduced grant and collaboration revenue.

• R&D Expenses Rise for Phase 3 Trial

  Research and development expenses increased by 33% to $19.5 million in Q1 2026, mainly driven by costs associated with the ongoing Phase 3 AURORA trial for Descartes-08 in myasthenia gravis.

• Secures $14.6M Through ATM Offering

  Cartesian Therapeutics raised approximately $14.6 million in net proceeds during Q1 2026 by selling 2,270,712 shares of common stock through its At-The-Market (ATM) equity offering program, which has an aggregate gross sales proceeds limit of up to $100.0 million.

auto_awesomeAnalysis

Cartesian Therapeutics' Q1 2026 financial results show a significant deterioration in performance, with net loss more than doubling year-over-year and revenue plummeting. The company continues to burn cash, primarily driven by increased research and development expenses for its lead product candidate, Descartes-08. However, the successful execution of an At-The-Market (ATM) offering, raising $14.6 million, provides crucial liquidity, extending the company's cash runway for at least the next 12 months. This capital raise, while dilutive, is essential for funding ongoing clinical trials and operations, mitigating immediate going concern risks.